Eisai Inc:企業のM&A・事業提携・投資動向

◆英語タイトル:Eisai Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
◆商品コード:DATA904C1980
◆発行会社(調査会社):MarketLine
◆発行日:2018年7月
◆ページ数:176
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD350 ⇒換算¥51,800見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD700 ⇒換算¥103,600見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD1,050 ⇒換算¥155,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketLine社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
MarketLine社の概要はこちらでご確認いただけます。



【レポートの概要】

Eisai Inc – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Summary

Marketline’s Eisai Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Eisai Inc since January2007.

Synopsis

Marketline’s Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.

Key Highlights

This report includes Eisai Inc’s contact information and business summary, tables, graphs, a list of partners and targets, a breakdown of financial and legal advisors, deal types, top deals by deal value, detailed deal reports, and descriptions and contact details of the partner, target, investor, and vendor firms, where disclosed.

The profile also includes detailed deal reports for all M&A, private equity, public offering, venture financing, partnership and divestment transactions undertaken by Eisai Inc. These deal reports contain information about target company financials, sources of financing, method of payment, deal values, and advisors for various parties, where disclosed.

Scope

- Provides intelligence on Eisai Inc’s M&A, strategic partnerships and alliances, capital raising and private equity transactions.
- Detailed reports of various financial transactions undertaken by Eisai Inc and its subsidiaries since 2007.
- Information about key financial and legal advisors for Eisai Inc’s financial deals transactions.
- Financial deals tables and charts covering deal value and volumes trend, deal types and geography-based deal activity.

Reasons to buy

- Access comprehensive financial deals data along with charts and graph covering M&A, private equity, and partnerships and alliances.
- Form an independent opinion about Eisai Inc’s growth strategies through the organic and inorganic activities undertaken since 2007.
- Track your competitors’ business structure and growth strategies.

【レポートの目次】

Table of Contents
COMPANY OVERVIEW AND KEY FACTS 2
TABLE OF CONTENTS 4
LIST OF TABLES 5
LIST OF FIGURES 5
TARGETS AND PARTNERS 6
MERGERS & ACQUISITIONS 7
Mergers and Acquisitions – Deal reports 7
PARTNERSHIP 13
Partnership – Overview 13
Partnership – Deal reports 14
DIVESTMENTS 163
Divestments – Overview 163
Divestments – Deal reports 164
APPENDIX 166
Contact Us 166
About MarketLine Financial Deals Database 166
Deal Definition and Methodology 168
About MarketLine 175

List of Tables
Table 1: Eisai Inc partnership volume and value trend (2014-YTD2018)
Table 2: Eisai Inc partnership trend by key deal type (2014-YTD2018)
Table 3: Eisai Inc divestments volume and value trend (2014-YTD2018)
Table 4: Eisai Inc divestments activity by geography (2014-YTD2018)

List of Figures
Figure 1: Eisai Inc partnership volume and value trend (2014-YTD2018)
Figure 2: Eisai Inc partnership trend by key deal type (2014-YTD2018)
Figure 3: Eisai Inc divestments volume and value trend (2014-YTD2018)
Figure 4: Eisai Inc divestments by geography (2014-YTD2018)

★海外企業調査レポート[Eisai Inc:企業のM&A・事業提携・投資動向]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Omaxe Ltd:企業の戦略・SWOT・財務情報
    Omaxe Ltd - Strategy, SWOT and Corporate Finance Report Summary Omaxe Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • AGRANA Beteiligungs-AG:企業の戦略・SWOT・財務分析
    AGRANA Beteiligungs-AG - Strategy, SWOT and Corporate Finance Report Summary AGRANA Beteiligungs-AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Bioneer Corp (064550):医療機器:M&Aディール及び事業提携情報
    Summary Bioneer Corp (Bioneer) is a molecular diagnostic company that develops and produces molecular research and molecular diagnostic products and instruments. The company’s major molecular research products include DNA/RNA amplification pre mixes, DNA/RNA preparation system, oligo synthesis and r …
  • United Continental Holdings Inc:戦略・SWOT・企業財務分析
    United Continental Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary United Continental Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • eNeura Inc:医療機器:M&Aディール及び事業提携情報
    Summary eNeura Inc (eNeura) formerly eNeura Therapeutics LLC is a medical device manufacturing company that offers portable, non-invasive transcranial magnetic stimulation devices for treating migraine. The company offers products such as flagship product and eNeura Spring TMS device, among others. …
  • leon-nanodrugs GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Leon-Nanodrugs GmbH (Leon-Nanodrugs) is a drug development company that discovers and develops nanotechnology based drug delivery systems. The company develops oral and parenteral products. Its products portfolio includes nanoparticles and drug-delivery-systems such as functionalized multila …
  • NanoRepro AG (NN6):製薬・医療:M&Aディール及び事業提携情報
    Summary NanoRepro AG (NanoRepro) is a manufacturer of fast-diagnostics and nutritional food supplements for home and clinical use. The company offers wide range of rapid diagnostic tests products in the areas of family planning, disease detection (preventive healthcare), food intolerances, allergies …
  • Mizuho Bank Ltd:企業のM&A・事業提携・投資動向
    Mizuho Bank Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mizuho Bank Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Tata Steel Group:企業のM&A・事業提携・投資動向
    Tata Steel Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Tata Steel Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • NSK Ltd (6471):企業の財務・戦略的SWOT分析
    NSK Ltd (6471) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Micro Focus International plc (MCRO):企業の財務・戦略的SWOT分析
    Micro Focus International plc (MCRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Encavis AG (CAP):企業の財務・戦略的SWOT分析
    Summary Encavis AG (Encavis), formally Capital Stage AG, is an independent power producer. It offer investment services such as asset sourcing, due diligence, management, and documentation of renewable energy assets. Encavis also provides technical services comprising monitoring, reporting, fault ma …
  • LifeNet Health Inc:医療機器:M&Aディール及び事業提携情報
    Summary LifeNet Health Inc (LifeNet Health) is a non-profit organization that specializes in regenerative medicine. It offers allograft bio-implants and organs for transplantation. The organization specializes in offering organ procurement, tissue banking and transplant services. It provides allogra …
  • Sosei Group Corp (4565):製薬・医療:M&Aディール及び事業提携情報
    Summary Sosei Group Corp (Sosei) is a biopharmaceutical company that develops and commercializes drugs. The company’s pipeline products include NorLevo, NVA237, QVA149 and SO-1105. Its NorLevo product is an oral emergency contraceptive; and SO-1105 is an antifungal agent, administered as a muco-adhe …
  • Dentsply Sirona Inc (XRAY):企業の財務・戦略的SWOT分析
    Dentsply Sirona Inc (XRAY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • SK Networks Co Ltd (001740):企業の財務・戦略的SWOT分析
    Summary SK Networks Co Ltd (SK Networks) is a marketing and distribution company. The company operates in diversified businesses including ICT marketing, automotive, hotel and resorts, rental appliances, and chemical material. It offers global trading in industrial materials such as steel, chemicals …
  • Norton Healthcare Inc-製薬・医療分野:企業M&A・提携分析
    Summary Norton Healthcare Inc (Norton Healthcare) is a healthcare service provider that offers medical services. The center offers services such as cancer care, bariatric and weight management, diabetes and endocrine, gastroenterology, clinical trials, pain management, bone marrow transplantation, d …
  • UCB Inc-製薬・医療分野:企業M&A・提携分析
    Summary UCB Inc (UCB), a subsidiary of UCB SA is a healthcare solutions provider that offers therapeutics. The company develops products with an emphasis on central nervous system and immunology therapeutic domains. Its products include cimzia, vimpat, keppra XR, neupro, tussionex pennkinetic, metad …
  • Medherant Ltd:企業の製品パイプライン分析
    Summary Medherant Ltd (Medherant) is a transdermal drug delivery patch company. The company develops and commercializes novel technologies for delivery of drugs through the skin using expertise in bioadhesives and polymer chemistry to treat pain, Alzheimer's disease, and for smoking cessation, hormo …
  • Shanghai Institute of Materia Medica Chinese Academy of Sciences-製薬・医療分野:企業M&A・提携分析
    Summary Shanghai Institute of Materia Medica Chinese Academy of Sciences (SIMM) is an educational research institute that offers research and development of traditional Chinese medicine. The institute provides solutions in the areas of drug discovery and drug development. It also provides studies of …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆